Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. Mr. Nelsen currently serves on the boards of directors of several publicly traded biotechnology companies, including Prime Medicine, Sana Biotechnology, and Hua Medicine, as well as a number of privately held biotechnology companies. He previously served on the boards of directors of several publicly traded biopharmaceutical companies, including VIR Biotechnology, Lyell Immunopharma, Seaport Therapeutics, Brii Biosciences, Neumora Therapeutics, Revolution Healthcare, Denali Therapeutics, Beam Therapeutics, and Karuna Therapeutics (subsequently acquired by Bristol Myers Squibb).

Mr. Nelsen received his B.S. from the University of Puget Sound in Economics and Biology and his MBA from the University of Chicago.